Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewsWire • 03/19/24
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio UpdateGlobeNewsWire • 03/12/24
Design Therapeutics, Inc. (DSGN) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 12/18/23
Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024GlobeNewsWire • 11/13/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGNPRNewsWire • 10/09/23
Design Therapeutics stock plunges on trial results for neuromuscular disease treatmentMarket Watch • 08/15/23
Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial ResultsGlobeNewsWire • 08/14/23
Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich AtaxiaGlobeNewsWire • 08/14/23
Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial ResultsGlobeNewsWire • 05/09/23
Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023GlobeNewsWire • 04/24/23
Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewsWire • 03/14/23
Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma ConferenceGlobeNewsWire • 02/08/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Design Therapeutics, Inc. - DSGNNewsfile Corp • 01/07/23
Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio ProgressGlobeNewsWire • 12/07/22
Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial ResultsGlobeNewsWire • 11/03/22
Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022GlobeNewsWire • 10/17/22
Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine SummitGlobeNewsWire • 09/22/22
Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial ResultsGlobeNewsWire • 08/08/22
Design Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare ConferenceGlobeNewsWire • 08/03/22